Allergan (AGN) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to Allergan (AGN) Tops Q4 EPS by 5c
February 23, 2016 8:23 AM EST
Allergan (NYSE: AGN) posted a solid 4Q leading Piper Jaffray analyst, David Amsellem, to reiterate his Overweight rating but trim his price target as estimates roll forward.
AGN reported non-GAAP diluted EPS of $3.41 on revenues of $4.2B, versus the Street estimates of $3.36 and $4.2B. Performance across several key product franchises remained strong, with total brand revenue in 4Q15 growing by 11% over 4Q14 (excluding foreign exchange headwinds and the erosion of the immediate-release form of Namenda due to generics).
The company has strong visibility on continued brisk volume growth for key... More
February 23, 2016 7:04 AM EST
Mizuho Securities maintained a Buy rating on Allergen (NYSE: AGN), and cut the price target to $330.00 (from $354.00), following the company's 4Q earnings report. AGN delivered a solid 4Q bottom line beat with revenues of $4.2B and EPS of $3.41 versus consensus estimates $4.2B and... More
